Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.
You may also be interested in...
GSK Gives Up Right To Buy Eniluracil Back From Adherex
Adherex has an “accelerated development plan” for the novel chemoenhancer GSK shelved in 2004.
Sanofi-Aventis To Assume Development Of Phase III Anticancer Agent S-1
Sanofi will pay Taiho Pharmaceutical up to $360 mil. for S-1, which combines two enzyme inhibitors with the 5-FU prodrug tegafur.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.